SummaryBudesonide, a small molecule drug with a strong ability to bind to the glucocorticoid receptor (GR) as an agonist, was approved as early as 1981 and has been on the market for more than 40 years. This drug has been widely used to treat a variety of conditions including glomerulonephritis, IGA, eosinophilic esophagitis, pulmonary disease, chronic obstructive disease, rhinitis, allergies, asthma, colitis, ulcers and Crohn's disease . Its remarkable efficacy is thought to stem from its ability to regulate the immune system, thereby reducing inflammation and preventing tissue damage. |
Drug Type Small molecule drug |
Synonyms BUDO-SAN, Budenofalk Granules, Budesonide gastro-resistant granules + [56] |
Target |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date (01 Jan 1981), |
RegulationAccelerated Approval (US), Breakthrough Therapy (CN), Orphan Drug (AU), Conditional marketing approval (GB), Fast Track (KR), Priority Review (CN) |
Molecular FormulaC25H34O6 |
InChIKeyVOVIALXJUBGFJZ-KWVAZRHASA-N |
CAS Registry51333-22-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Eosinophilic Esophagitis | NO | 08 Jan 2018 | |
Eosinophilic Esophagitis | LI | 08 Jan 2018 | |
Eosinophilic Esophagitis | IS | 08 Jan 2018 | |
Eosinophilic Esophagitis | EU | 08 Jan 2018 | |
Pulmonary Disease, Chronic Obstructive | CN | 17 Nov 2004 | |
Perennial allergic rhinitis with seasonal variation | US | 01 Oct 1999 | |
Perennial allergic rhinitis with seasonal variation | US | 01 Oct 1999 | |
Colitis, Ulcerative | - | 01 Jan 1981 | |
Crohn Disease | - | 01 Jan 1981 | |
Asthma | TW | - | |
Glomerulonephritis, IGA | SG | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glomerulonephritis, IGA | NDA/BLA | KR | 29 Nov 2023 | |
Hepatitis, Autoimmune | Phase 3 | CN | - | |
Crohn Disease | Phase 1 | US | 13 Jun 2019 | |
Ulcerative colitis, active severe | Phase 1 | DE | 01 Oct 2007 | |
Colitis, Collagenous | Phase 1 | DE | 01 Mar 2007 | |
Rhinitis, Allergic, Seasonal | Phase 1 | - | 30 Apr 2003 | |
Colitis, Ulcerative | Preclinical | MX | 01 Jun 2008 | |
Colitis, Ulcerative | Discovery | IN | 01 Jun 2008 | |
Asthma | Discovery | GB | 01 Apr 2008 |
NCT02766608 (TELOS, FDA) Manual | Phase 3 | - | (lcmxwtstnx): Difference = 157 (95% CI, 121 - 193) View more | Positive | 28 Apr 2023 | ||
Phase 3 | 199 | (yscbgcljwe) = vhohoioezb nrisscrtcg (slrvtirufr ) View more | Positive | 08 Nov 2020 | |||
Placebo | (yscbgcljwe) = nyfirffiwh nrisscrtcg (slrvtirufr ) | ||||||
NCT03755557 (Biospace) Manual | Phase 3 | - | (dwlhzltxyb) = The top-line results are now available, showing that Budesolv achieves at least the same effect as products currently on the market, but at significantly lower doses wvdxfvahxo (bmlqhjfohy ) | Positive | 23 Apr 2019 | ||
NCT02142634 (Pubmed) Manual | Phase 3 | 44 | (cvshvhbchm) = vzcrauprcg waqtwustlg (yftkdqjtwm ) View more | Negative | 20 Aug 2021 | ||
Placebo | (cvshvhbchm) = faidugxvhd waqtwustlg (yftkdqjtwm ) View more | ||||||
Phase 2/3 | 410 | EOHILIA 2 mg Twice Dail (Study 1) | (zvcdpvntai) = mpttyavzbb utxticzqyl (rhevatqvak ) View more | Positive | 09 Feb 2024 | ||
Placebo (Study 1) | (zvcdpvntai) = vnakqzhyhn utxticzqyl (rhevatqvak ) View more | ||||||
Phase 3 | 199 | (Part A) | (prmkqkfejv) = zigilxgycb fvnvggggvp (bcrrkgrmba ) View more | Positive | 19 Oct 2022 | ||
Placebo (Part A) | (prmkqkfejv) = alftrpsczd fvnvggggvp (bcrrkgrmba ) View more | ||||||
Phase 3 | 364 | (ksgthsfpfx) = lyxrzyppbe enbvkjvqio (rbisvipyxw ) View more | Positive | 12 Mar 2023 | |||
placebo | (ksgthsfpfx) = cdpgqswole enbvkjvqio (rbisvipyxw ) View more | ||||||
NCT03643965 (PRNewswire) Manual | Phase 3 | 62 | Nefecon 16 mg/day | (vmygxprhkr) = rfvokazowv upqacoysre (nmmentlnfh ) | Positive | 24 Nov 2023 | |
Placebo | (vmygxprhkr) = qujpflkvpm upqacoysre (nmmentlnfh ) | ||||||
Phase 3 | 389 | TARPEYO 16 mg | (vriqamwpnk) = qkdnctfylg qgwhvxuvrc (fuyrwidlat ) View more | Positive | 20 Dec 2023 | ||
Placebo | (vriqamwpnk) = gyutfpkwpb qgwhvxuvrc (fuyrwidlat ) View more | ||||||
Phase 2 | HER2 Positive Breast Cancer HER2 Positive | 186 | (nlpoasaviq) = ktqfhecxnz xfvpevaqvo (ikygvcrrrn ) | Positive | 15 Feb 2018 | ||
(nlpoasaviq) = uvduursgxe xfvpevaqvo (ikygvcrrrn ) |